Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Zepbound Switching: How to Transition From or To Other GLP-1/GIP Drugs Safely At a glance Drug / Zepbound (tirzepatide), Eli Lilly Drug class / Dual GIP and GLP-1 receptor agonist Approved indication / Chronic weight management in adults with BMI 30, or 27 with one weight-related comorbidity Dosing frequency / Once weekly subcutaneous injection Starting dose / 2.5 mg weekly, escalated every 4 weeks Maximum dose / 15 mg weekly Key trial / SURMOUNT-1 (N=2,539): 20.9% mean body-weight loss at 72 weeks on 15 mg Half-life / Approximately 5 days (supports once-weekly dosing) Common switch scenarios / Semaglutide to tirzepatide, liraglutide to tirzepatide, tirzepatide to oral semaglutide FDA approval date / November 8, 2023 (weight management indication) How Zepbound Works: Mechanism at the Receptor Level Zepbound binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
To smooth the transition, you can split the difference take Mondays usual dose, then take the next dose on Thursday (3 days later), then settle into your Friday schedule going forward
Many studies have confirmed that higher levels of glutathione are important for normal cellular functions and protection against carcinogens
For the KLOW blend as a whole, no controlled human safety data exist
PMID: 35
US$ 21.11
US$ 27.64
US$ 25.52
